News
Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) are pitted against each other, but only one can be my preferred healthcare stock. Where to invest $1,000 right now? Our analyst team just revealed ...
With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...
HSBC has once again reduced its price target for Eli Lilly, this time dropping it to $675 from $700 while maintaining a ...
Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.
As its obesity medication Wegovy loses a sizable portion of the market to Eli Lilly and Company (NYSE:LLY)’s competing ...
Eli Lilly (NYSE: LLY) is encouraged by trial data for its latest weight-loss and diabetes medications. Where to invest $1,000 ...
Novo Nordisk’s new top executive will need to help the company close the gap with Eli Lilly, fend off emerging rivals and ...
Eleven-year follow-up data continue to show the invasive disease-free survival benefit for node-positive patients seen in previous analyses.
The success of Eli Lilly & Co. 's weight-loss and diabetes drugs has pushed the company's stock to new heights, helping the ...
Novo Nordisk A/S' CEO transition sparks governance concerns, but internal succession ensures stability. Click for my updated ...
Zepbound outperformed Nordisk's Wegovy in terms of weight loss, solidifying Lilly's leadership in the anti-obesity drug ...
Wegovy-maker Novo Nordisk said on Friday its CEO Lars Fruergaard Jorgensen will step down over concerns the company is losing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results